Anika Announces Planned CFO Transition
June 02 2020 - 4:05PM
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint
preservation and regenerative therapies company with products
across the orthopedic early intervention continuum of care, today
announced that Sylvia Cheung, Chief Financial Officer, has informed
the Board of Directors of her decision, following a period of
transition, to step away from her role at Anika effective August
21, 2020. Anika has initiated a search to identify Ms.
Cheung’s successor. If a successor has not been identified prior to
Ms. Cheung’s planned departure, the Company may request that she
continue as a special advisor for a period of time to help ensure a
smooth transition.
“Sylvia is an exemplary leader who has made many meaningful
contributions to Anika over the years,” said Cheryl R. Blanchard,
Ph.D., President and Chief Executive Officer of Anika. “On behalf
of the Board and the entire company, I want to thank Sylvia for her
steady leadership. Among other things, she has helped develop and
begin execution of our transformation strategy, and has built
strong and high performing finance and accounting, investor
relations and information technologies functions that will support
our ongoing success. We appreciate Sylvia’s input in the search
process and are confident she will succeed in whatever she chooses
to do next.”
“I am proud of what we have built over the last 15 years. It has
been an extraordinary experience for me, and I am especially
pleased that the Company is well positioned for its next phase of
growth,” said Ms. Cheung. “I look forward to working closely with
Cheryl and the Board to identify the right candidate and to help
ensure a smooth transition. As I look to the future, I am confident
in Anika’s long-term business plan and in Cheryl’s and the
management team’s ability to achieve the Company’s strategic and
financial goals. I will be following Anika’s growth and success for
years to come.”
About Anika TherapeuticsAnika
Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated
joint preservation and regenerative therapies company based in
Bedford, Massachusetts. Anika is committed to delivering therapies
to improve the lives of patients across a continuum of care from
osteoarthritis pain management to joint preservation and
restoration. The Company has close to three decades of global
expertise commercializing more than 20 products. For more
information about Anika, please visit
www.anikatherapeutics.com.
For Investor Inquiries: Anika Therapeutics, Inc. Sylvia Cheung,
781-457-9000 Chief Financial
Officerinvestorrelations@anikatherapeutics.com |
For Media Inquiries: W2O Group Jeremy Berrington,
312-241-1995jberrington@w2ogroup.com |
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Apr 2023 to Apr 2024